연구성과로 돌아가기
2023 연구성과별 연구자 정보 (307 / 2675)
※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Document Title | Author Full Name | Author Short Name | Index | Corresponding | Address | ResearcherID | ResearcherID Author Name | ORCID | ORCID Author Name | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
| Below-Knee Prosthetic Bypass Is a Viable Option for Limb Salvage in Patients with Extensive Femoropopliteal Occlusive Disease | Kim, Hyung-Kee | Kim, HK | 6 | 교신저자 | Kyungpook Natl Univ, Sch Med, Div Vasc & Endovasc Surg, Dept Surg,Chilgok Hosp, Daegu, South Korea | JBR-8125-2023 | Kim, Hyung-Kee | 0000-0002-4436-7424 | Kim, Hyung-Kee | hkkim6260@knu.ac.kr; |
| Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis | Kang, Y-K. | Kang, YK | 1 | Univ Ulsan, Oncol Dept, Asan Med Ctr, Coll Med, Seoul, South Korea | ABL-4264-2022 | Kang, Yoon-Koo | ||||
| Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis | Qin, S. | Qin, S | 2 | Nanjing Univ Chinese Med, Nanjing Jingdu Hosp, Canc Ctr, Jinling Hosp, Nanjing, Peoples R China | ||||||
| Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis | Lee, K-W. | Lee, KW | 3 | Seoul Natl Univ, Internal Med Dept, Bundang Hosp, Seongnam, South Korea | ||||||
| Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis | Oh, S. C. | Oh, SC | 4 | Korea Univ, Dept Internal Med, Seoul, South Korea | ||||||
| Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis | Kim, I-H. | Kim, IH | 5 | Catholic Univ Korea, Coll Med, Songeui Med Campus, Med Oncol, Seoul, South Korea | ||||||
| Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis | Kim, J. G. | Kim, JG | 6 | Kyungpook Natl Univ, Dept Oncol, Chilgok Hosp, Daegu, South Korea | ||||||
| Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis | Li, Y. | Li, Y | 7 | Hebei Med Univ North Gate, Gastroenterol Dept, Hosp 4, Shijiazhuang, Hebei, Peoples R China | ||||||
| Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis | Yan, Z. | Yan, Z | 8 | Tianjin Med Univ, Canc Inst & Hosp, Dept Integrat Oncol, Tianjin, Peoples R China | ||||||
| Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis | Li, J. | Li, J | 9 | Tongji Univ, Southern Div, Dept Oncol, Shanghai East Oriental Hosp, Shanghai, Peoples R China | ||||||
| Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis | Bai, L-Y. | Bai, LY | 10 | China Med Univ Hosp, Hematol Med Oncol, New Taipei, Taiwan | ||||||
| Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis | Chan, C. P. K. | Chan, CPK | 11 | Amgen Hong Kong, Med Affairs Dept, Hong Kong, Peoples R China | ||||||
| Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis | Yusuf, A. | Yusuf, A | 12 | Amgen Headquarters USA, Global Med Org, Thousand Oaks, CA USA | ||||||
| Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis | Zahlten-Kuemeli, A. | Zahlten-Kuemeli, A | 13 | Amgen Inc SSF, Oncol Dept, San Francisco, CA USA | ||||||
| Bemarituzumab (bema)+FOLFOX6 as first-line treatment in patients with FGFR2b overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer (G/ GEJC): East Asia subgroup of FIGHT final analysis | Taylor, K. | Taylor, K | 14 | Amgen Ltd, Biostat, Uxbridge, Middx, England |
페이지 이동: